Approved and current. Effective starting 1/27/2023. COA-456256 (version 2.0) Human CYP3A5 + P450 Reductase + Cytochrome b5 SUPERSOMES COA

Discovery Life Sciences 6 Henshaw Street Woburn, MA 01801 Tel: (866) 838-2798 info@dls.com https://www.dls.com/

Human CYP3A5 + P450 Reductase + Cytochrome b₅ SUPERSOMES[™]

Catalog Number....456256 Lot Number.....2402262 Storage Conditions..STORE AT -80°C Date Released2024 March Expiration Date......2034 March

| Package Contents | 0.5 nmole cytochrome P450 in 0.5 mL |
|---------------------------------------|--|
| Protein Content | 4.8 mg/mL in 100 mM potassium phosphate (pH 7.4) |
| Cytochrome c Reductase Activity | 3100 nmole/(min x mg protein) |
| Cytochrome P450 Content | 1000 pmole per mL |
| Cytochrome b ₅ Content | 1200 pmole per mg protein |
| Testosterone 6β-Hydroxylase Activity. | 79 pmole product/(min x pmole P450) |

PRODUCT DESCRIPTION: This activity is catalyzed by CYP3A5 which is expressed from human CYP3A5 cDNA using a baculovirus expression system. Baculovirus infected insect cells (BTI-TN-5B1-4) were used to prepare these microsomes. These microsomes also contain cDNA-expressed human P450 reductase and human cytochrome b₅. A microsome preparation using wild type virus (Catalog No. 456201) should be used as a control for native activities.

ADVICE

- Thaw rapidly in a 37°C water bath. Keep on ice until use.
- Aliquot to minimize freeze-thawing cycles. Minimal loss in catalytic activity was observed after 10 freeze thaw cycles.
- Metabolite production with testosterone is approximately linear for 20 minutes (see graph above). Other substrates may not exhibit similar linearity with respect to incubation time.

HAZARD WARNING:

The product was produced using baculovirus (*Autographa californica*) infected insect cells (BTI-TN-5B1-4). This virus is not known to be pathogenic to humans or other mammals.

SAFETY RECOMMENDATIONS:

When using this product, follow good laboratory safety procedures:

- Do not eat, drink or smoke.
- Avoid contact with skin or eyes.
- Do not inhale aerosols.
- Do not pipette by mouth.
- Wear suitable protective clothing, gloves and eye protection.
- Steam sterilize product or treat product with a 1% solution of sodium hypochlorite prior to disposal.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Approved and current. Effective starting 1/27/2023. COA-456256 (version 2.0) Human CYP3A5 + P450 Reductase + Cytochrome b5 SUPERSOMES COA Discovery Life Sciences 6 Henshaw Street Woburn, MA 01801 Tel: (866) 838-2798 info@dls.com https://www.dls.com/

PRIMARY ASSAY METHOD: A 0.50 mL reaction mixture containing 10 pmole P450, 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 0.4 U/mL glucose-6-phosphate dehydrogenase, 3.3 mM magnesium chloride and 0.2 mM testosterone in 100 mM potassium phosphate (pH 7.4) was incubated at 37°C for 10 minutes. After incubation, the reaction was stopped by the addition of 250 μ L 5 μ M 6 β hydroxytestosterone-D7 in acetonitrile and centrifuged (10,000 x g) for 3 minutes. The product was detected by LC-MS/MS using its Q1 mass and Q3 mass with positive polarity and quantitated by comparing the peak area ratio to a standard curve of 6 β hydroxytestosterone.



ANALYTICAL METHOD:

Materials

| Column | 2.1 x 50 mm 5µm C18 HPLC |
|----------------|---------------------------------------|
| Mobile Phase A | 0.1% Formic Acid in dH ₂ O |
| Mobile Phase B | 0.1% Formic Acid in Acetonitrile |

Mass Transitions of MRM

| Compound | Q1 Mass (amu) | Q3 Mass (amu) | |
|----------------------------|---------------|---------------|--|
| Analyte- | 305.1 ±0.2 | 269.1 ±0.2 | |
| 6β -Hydroxytestosterone | | | |
| Internal Standard | 312.1 ±0.2 | 276.1 ±0.2 | |
| 6β -Hydroxytestosterone-D7 | | | |

Gradient Separation Conditions

| Time | Flow Composition of | Flow Composition of Flow Rate | |
|----------|---------------------|-------------------------------|-----------|
| (minute) | Mobile Phase A (%) | Mobile Phase B (%) | (µL /min) |
| 0.0 | 75 | 25 | 400 |
| 1.0 | 50 | 50 | 400 |
| 1.2 | 50 | 50 | 400 |
| 1.3 | 10 | 90 | 400 |
| 1.8 | 10 | 90 | 400 |
| 1.9 | 50 | 50 | 400 |
| 2.7 | 50 | 50 | 400 |
| 2.8 | 75 | 25 | 400 |
| 3.5 | 75 | 25 | 400 |

For Research Use Only. Not for use in diagnostic or therapeutic procedures. © DLS Approved and current. Effective starting 1/27/2023. COA-456256 (version 2.0) Human CYP3A5 + P450 Reductase + Cytochrome b5 SUPERSOMES COA Discovery Life Sciences 6 Henshaw Street Woburn, MA 01801 Tel: (866) 838-2798 info@dls.com https://www.dls.com/

Cliffi-

21 March 2024

Quality Assurance

Date

| Revision History | | | | | |
|------------------|------------|--|---------------|-----------------|--|
| Rev. | Change No. | Description of Change | Revised By | Revised Date | |
| 1 | CC-02544 | Updated to Corning branding, protected variable fields, replace safety section with safety statement and clarify SDS [Safety Data Sheet] information, addition of QA signature and date | L. Brown | 7/23/14 | |
| 2 | CC-13033 | Method section was updated to align with the changes implemented in WB-MP-171 rev. 1. Analytical acquisitions method was converted from text to tables. | C. McCullough | 7/24/2019 | |

For Research Use Only. Not for use in diagnostic or therapeutic procedures. © DLS